Where to Buy Selank: The Pharmacy Counter Is Not an Option

Where to buy selank is usually answered with a list of shops. That skips the more useful step, which is working out what each type of seller is actually offering, what documentation comes with it, and what happens if the package never arrives or arrives wrong. Those three things vary far more between channels than price does.

Four channels genuinely sell Selank to a US buyer: domestic research-chemical suppliers, overseas marketplace listings, grey-market resellers operating through forums and messaging apps, and nootropic retailers offering a pre-mixed nasal spray. A fifth, the compounding pharmacy, appears in a lot of search results and cannot supply it. That closure is not a technicality, so it is worth doing first.

We link one supplier on this page and earn a commission if you buy through it, which our affiliate disclosure sets out. The comparison below includes the tests that supplier's February certificate does not carry and its June batch does.

A compounding pharmacy operating under section 503A of the Federal Food, Drug and Cosmetic Act may only compound from a bulk drug substance if one of three conditions holds. The substance complies with a United States Pharmacopeia or National Formulary monograph. Or, if no monograph exists, it is a component of an FDA-approved drug product. Or, if neither is true, it appears on FDA's 503A bulks list. FDA states this on its bulk drug substances page, content current as of 14 May 2026.

Selank fails each condition. No USP or NF monograph exists for it. No FDA-approved drug product contains it, because none has ever been approved. And it is absent from the 503A bulks list. FDA's own page adds a second requirement on top: any bulk substance a pharmacy compounds with must arrive with a valid certificate of analysis and must have been made by an establishment registered with FDA under section 510 of the Act. Even a pharmacy willing to ignore the first test would struggle with the second, because the research-grade supply chain is not built to that standard.

This is where Selank differs from some peptides that share a shelf with it. Our write-up on the compounded route that does exist for NAD+ covers a substance that sits in FDA's category 1, where the agency has said it does not intend to act against compounders meeting stated conditions. Selank has nothing equivalent. Any site telling you a clinic can arrange it has either confused it with a different compound or is describing something the pharmacy should not be doing.

This is the channel most buyers end up in. A US-based supplier lists a lyophilised vial, usually 5 or 10 mg, labelled for laboratory research use and not for human consumption. Payment is by card, dispatch is same or next day from a domestic warehouse, and the meaningful variable between sellers is documentation.

What you get: a sealed vial of powder, a lot number, and in the better cases a certificate of analysis tied to that lot. What you do not get: a prescriber, a pharmacist, a patient label, dosing guidance, or a recall path. The seller is a seller of chemicals, and the legal basis of the sale is that the material is not for human use.

The risk profile is different from the other three channels. Transit risk is low because nothing crosses a border. Recourse is better because a card payment leaves a chargeback route and a US business has a published returns policy. The risk that remains is quality, and quality here means one document. If the certificate is generic rather than lot specific, or reports a purity figure with no chromatogram, or omits contamination testing, you have a nicely designed page and very little evidence.

Cost sits at the low end. The listing we link is a 10 mg vial at $47.50, reduced to $23.75 with the code PEPTIDEDECK, which is $2.38 per milligram. That per-milligram figure is the only honest way to compare a vial against a spray, and it is why the format comparison further down is not a fair fight on price.

The same powder is listed on bulk chemical marketplaces at a fraction of the domestic price, often by the gram rather than the vial. The listings look industrial because they are: the seller is usually a synthesis house or a trading company, and the buyer they are set up for is a laboratory placing a purchase order.

What changes is everything after checkout. A parcel arriving from overseas passes through customs, and FDA's personal importation guidance is clear that an unapproved drug offered for import may be refused entry. A refused parcel is not a refund. Transit also takes weeks, and a lyophilised peptide sitting in a container or a sorting facility is not being temperature controlled by anyone.

The documentation problem compounds. Where a domestic supplier publishes a certificate you can open before ordering, marketplace sellers frequently supply one on request, after payment, and often for a batch rather than your batch. Payment is often by bank transfer, which ends your recourse at the moment the money leaves.

Cost per milligram is genuinely lower, sometimes dramatically. Whether that is a saving depends entirely on the proportion of parcels that arrive, which is not a number anyone publishes and which we cannot verify. Treat the headline price as the price of a lottery ticket rather than of a vial.

The third channel is individuals and small operations selling through forums, group chats, social platforms and messaging apps. They usually buy in bulk from channel two and repackage, sometimes reconstituting and filling vials themselves.

Two things distinguish this channel and neither is favourable. The first is that repackaging breaks the chain between the certificate and the vial. Whatever testing the original bulk received described a drum of powder, not the vial a reseller filled on a kitchen counter. The second is payment: peer-to-peer transfers and cryptocurrency are the norm, and both are designed to be final. There is no chargeback, no seller of record and no returns policy.

This is also the channel where FDA's stated concern becomes most concrete. The agency's worry about Selank is immunogenicity from aggregation and peptide-related impurities, which is a manufacturing and handling question. Repackaging by an unqualified party is precisely the step that introduces aggregation and contamination while producing no new documentation. The same logic applies across the withdrawn-nomination peptides, which is why our MOTS-c legal-status guide reaches the same conclusion about resellers from a different starting point.

Selank reaches most consumers as a pre-mixed nasal spray sold by nootropic retailers, typically a small bottle at a stated concentration. It is the most convenient format on the market and the one that raises the most questions.

You are buying a solution rather than a powder, which means someone has already reconstituted it, added preservatives or a carrier, filled and sealed the bottle, and assigned it a shelf life. Every one of those steps is a manufacturing step, and none of the retailers in this category are drug manufacturers. A certificate for the raw peptide, if one is offered at all, says nothing about the sterility, concentration or stability of the finished solution in the bottle.

The economics are unfavourable too. A spray contains a small quantity of peptide in a lot of solvent, so the price per milligram of actual Selank is typically many times that of a vial. Since we cannot cite spray prices that resolve to a live listing, take that as a structural point rather than a figure: you are paying for convenience, dilution and a bottle.

Ascension, the supplier we link, sells the lyophilised 10 mg vial and does not sell a spray. That is worth stating plainly rather than implying otherwise. If a nasal spray is specifically what you want, this page is not pointing you at one, and our companion piece on the spray-versus-vial format question goes through what changes between them.

The table below sets the five channels against what you receive, what can go wrong, and how cost behaves. Only the domestic vial price is a figure we have verified against a live listing; the rest are structural, because prices in the other channels either move constantly or cannot be checked from a public page.

Read the risk column as the deciding one. Price differences between these channels are smaller than the differences in what happens when something goes wrong, and the channel that looks cheapest is usually the one where nothing is recoverable.

If the decision were ours, the domestic research supplier with a published, lot-specific certificate wins on the only axis that separates these channels meaningfully: the amount of checkable evidence attached to the specific vial you receive. Ascension publishes a certificate from MZ Biolabs for lot 29-01260229 reporting 99.32 percent purity by HPLC-UV, identity confirmed by mass spectrometry at 751.47 daltons against an expected 751.43, and a measured quantity of 12.29 mg against a 10 mg label.

It is also fair to say what that February certificate does not contain, because it is the test FDA's concern points at. There is no endotoxin, LAL, pyrogen, sterility or heavy metals testing on it. The June batch, 29-05260628, does carry all of them, including kinetic chromogenic LAL endotoxin testing to USP Chapter 85 and a rapid sterility screen from a different laboratory, and the vendor's Semax listing shows the same February-to-June change. So which tests you get is a batch question, and the right response is to read every certificate on the product page rather than only the clickable link, and to confirm which batch is being shipped.

If you want the criteria written out rather than the channels, our supplier vetting guide for Selank runs the full checklist. For the precise legal position, including FDA's own wording, our page on buying Selank without a prescription is the careful one.